Jacob Claire, Szilagyi Corinne, Allen Janet M, Bertrand Claude, Lagente Vincent
Pfizer Global R&D, Fresnes Laboratories, Department of Biology, 3-9 rue de la Loge, 94265 Fresnes, France.
Br J Pharmacol. 2004 Sep;143(2):257-68. doi: 10.1038/sj.bjp.0705927. Epub 2004 Aug 16.
We investigated the generation of reactive oxygen species (ROS) from bronchoalveolar lavage (BAL) cells of either control or LPS-exposed rats and the effects of PDE4 inhibitors on ROS production. The PDE4 inhibitors, rolipram and Ariflo (cilomilast, SB 207499) dose-dependently (0.1-10 microm) inhibited fMLP-induced superoxide anion (O(2)(-)) production (IC(50)s: 0.03 and 0.55 microm, respectively) in BAL cells of Wistar rats collected 3 h after an LPS-aerosol (200 micrograms ml(-1), 1 h). These BAL contained 85-95% neutrophils (BAL cells enriched in neutrophils). In contrast, BAL cells collected at the end of the challenge contained only macrophages and in these conditions, rolipram and Ariflo (0.1-10 microm) could only inhibit 25 and 45% of fMLP-induced O(2)(-) release, respectively. We also observed that the inhibition of p44/42(MAPK) by PD98059 (1-10 microm) increased O(2)(-) release by BAL cells enriched in neutrophils, but not by macrophages, and prevented the inhibition of O(2)(-) production induced by PDE4 inhibitors. Western blot analysis showed that PDE4 inhibitors strongly activated p44/42(MAPK) in BAL cells enriched in neutrophils but not in macrophages. And in these cells, PDE4 and p44/42(MAPK) were co-immunoprecipitated by a polyclonal anti-PDE4 antibody. The following cell permeable-cAMP analogues, dbcAMP (10 microm-1 mm), 8-CPT-cAMP (1 mm) and 8-pMeOPT-2'-O-Me-cAMP (0.5 mm), could not reduce fMLP-induced O(2)(-) production and both PKA inhibitors, PKA inhibitor 14-22 amide myristoylated (50 nm-1 microm) and H-89 (100 nm-1 microm), did not affect the decrease of O(2)(-) release induced by PDE4 inhibitors in BAL cells enriched in neutrophils. These data suggest that PDE4 inhibitors decreased fMLP-induced O(2)(*-) release in BAL cells enriched in neutrophils but not in macrophages, through p44/42(MAPK) activation by a cAMP- and a PKA-independent mechanism.
我们研究了对照大鼠或暴露于脂多糖(LPS)的大鼠支气管肺泡灌洗(BAL)细胞中活性氧(ROS)的产生,以及磷酸二酯酶4(PDE4)抑制剂对ROS产生的影响。PDE4抑制剂咯利普兰和阿瑞吡坦(西洛司特,SB 207499)在剂量依赖性(0.1 - 10微摩尔)下抑制了Wistar大鼠在LPS气雾剂(200微克/毫升,1小时)吸入3小时后收集的BAL细胞中fMLP诱导的超氧阴离子(O₂⁻)产生(IC₅₀分别为0.03和0.55微摩尔)。这些BAL细胞中含有85 - 95%的中性粒细胞(富含中性粒细胞的BAL细胞)。相比之下,在刺激结束时收集的BAL细胞仅含有巨噬细胞,在这些条件下,咯利普兰和阿瑞吡坦(0.1 - 10微摩尔)分别只能抑制fMLP诱导的O₂⁻释放的25%和45%。我们还观察到,PD98059(1 - 10微摩尔)对p44/42丝裂原活化蛋白激酶(MAPK)的抑制增加了富含中性粒细胞的BAL细胞而非巨噬细胞的O₂⁻释放,并阻止了PDE4抑制剂诱导的O₂⁻产生的抑制。蛋白质免疫印迹分析表明,PDE4抑制剂在富含中性粒细胞的BAL细胞中强烈激活p44/42 MAPK,但在巨噬细胞中则不然。并且在这些细胞中,PDE4和p44/42 MAPK被多克隆抗PDE4抗体共免疫沉淀。以下细胞可渗透的环磷酸腺苷(cAMP)类似物,二丁酰环磷腺苷钙(dbcAMP,10微摩尔 - 1毫摩尔)、8 - 氯苯硫基 - cAMP(8 - CPT - cAMP,1毫摩尔)和8 - 对甲氧基苯氧基 - 2'-O - 甲基 - cAMP(8 - pMeOPT - 2'-O - Me - cAMP,0.5毫摩尔),不能降低fMLP诱导的O₂⁻产生,并且两种蛋白激酶A(PKA)抑制剂,肉豆蔻酰化的PKA抑制剂14 - 22酰胺(50纳米 - 1微摩尔)和H - 89(100纳米 - 1微摩尔),均不影响PDE4抑制剂诱导的富含中性粒细胞的BAL细胞中O₂⁻释放减少。这些数据表明,PDE4抑制剂通过一种不依赖cAMP和PKA的机制激活p44/42 MAPK,从而减少了富含中性粒细胞的BAL细胞而非巨噬细胞中fMLP诱导的O₂⁻释放。